Table 3.
Demographic and clinical data in patients with axSpA by presence of LSTV
| axSpA (n=177) | p-value | ||
|---|---|---|---|
| Without LSTV (n=126) | With LSTV (n=51) | ||
| Age (yr) | 38.00 [30.00, 47.25] | 40.00 [28.00, 46.00] | 0.902 |
| Sex, male | 59 (46.8) | 32 (62.7) | 0.055 |
| BMI (kg/m²) | 28.17 [24.79, 31.96] | 26.75 [23.76, 29.05] | 0.105 |
| Smokers | 50 (39.7) | 18 (35.3) | 0.464 |
| Alcohol drinking | 8 (6.3) | 4 (7.8) | 0.636 |
| Martial status, married | 101 (80.2) | 33 (64.7) | 0.077 |
| Educational status, high school or university | 60 (47.6) | 32 (62.7) | 0.068 |
| Family history | 24 (19.0) | 13 (25.5) | 0.340 |
| Age at diagnosis (yr) | 36.00 [26.00, 42.25] | 30.00 [23.00, 42.00] | 0.182 |
| Symptom duration (yr) | 1.00 [0, 5.25] | 3.00 [1.00, 6.00] | 0.035* |
| IBP positive | 95 (75.4) | 33 (64.7) | 0.150 |
| Use of DMARD | 104 (82.5) | 44 (86.3) | 0.543 |
| Use of DMARD group (n=148) | 0.176 | ||
| Regular NSAID | 45 (43.3) | 13 (29.5) | |
| On demand NSAID | 20 (19.2) | 7 (15.9) | |
| csDMARD±regular NSAID | 11 (10.6) | 6 (13.6) | |
| csDMARD±on demand NSAID | 8 (7.7) | 9 (20.5) | |
| bDMARD±csDMARD±NSAID | 20 (19.2) | 9 (20.5) | |
| HLA-B27 positive (n=109 vs. 63) | 40 (36.7) | 22 (52.4) | 0.079 |
| r-axSpA/nr-axSpA | 67 (53.2)/ 59 (46.8) | 32 (62.7)/ 19 (37.3) | 0.245 |
Values are presented as median [interquartile range, per 25~75] or number (%). LSTV: lumbosacral transitional vertebrae, axSpA: axial spondyloarthritis, nr-axSpA: non-r-axSpA, r-axSpA: radiographic axSpA, BMI: body mass index, IBP: inflammatory back pain according to ASAS criteria, ASAS: Assessment of Spondyloarthritis International Society, DMARD: disease-modifying anti-rheumatic drug, NSAID: nonsteroidal anti-inflammatory drug, csDMARD: conventional synthetic DMARD, bDMARD: biologic DMARD. *Statistically significant data set p<0.05.